Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

R, Dummer; A, Hauschild; M, Santinami; V, Atkinson; M, Mandalà; JM, Kirkwood; Sileni V, Chiarion; J, Larkin; M, Nyakas; C, Dutriaux; A, Haydon; C, Robert; L, Mortier; J, Schachter; T, Lesimple; R, Plummer; K, Dasgupta; E, Gasal; M, Tan; GV, Long; D, Schadendorf

doi:10.1056/nejmoa2005493

Public

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

Shared by NobleBlocks on Sep 2, 2020 • 12:00 AM UTC

Authors:

Dummer R

Hauschild A

Santinami M

Abstract

Background In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!